Clinical Trial Update: Nevanac 3-Month Safety Study With QID Dosing [Phase 3]

View source ↗

Summary

A Phase 3 3-month safety study evaluating Nevanac (nepafenac) administered four times daily in cataract patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• Nevanac (nepafenac)

Snippet

Sponsor: Alcon Research | Conditions: Cataract | Phase 3 | Status: COMPLETED